Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ProQR Therapeutics II B.V.”

19 pharma patents match "ProQR Therapeutics II B.V." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 19
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 19 pharmaceutical patents matching "ProQR Therapeutics II B.V." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

19 results for “ProQR Therapeutics II B.V.” · 30,257 patents in full index Clear search

  1. US 12275937

    Stereospecific linkages in RNA editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  2. US 12203072

    Chemically modified single-stranded rna-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  3. US 12180471

    Antisense oligonucleotides for the treatment of Stargardt disease

    ProQR Therapeutics II B.V. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  4. US 12018257

    Single-stranded RNA-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  5. US 11920132

    Oligonucleotide therapy for Leber congenital amaurosis

    ProQR Therapeutics II B.V. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  6. US 11851656

    Chemically modified single-stranded RNA-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  7. US 11649454

    Single-stranded RNA-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  8. US 11479771

    Antisense oligonucleotides for the treatment of eye disease

    ProQR Therapeutics II B.V. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  9. US 11123360

    Oligonucleotides to treat eye disease

    ProQR Therapeutics II B.V. · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  10. US 10988763

    Single-stranded RNA-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted
  11. US 10941402

    Chemically modified single-stranded RNA-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  12. US 10900041

    Antisense oligonucleotides for use in treating Alzheimer's disease

    ProQR Therapeutics II B.V. · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted
  13. US 10889817

    Oligonucleotide therapy for Leber Congenital Amaurosis

    ProQR Therapeutics II B.V. · Granted Jan 12, 2021 · Expires Jan 7, 2041

    granted
  14. US 10760076

    Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion

    ProQR Therapeutics II B.V. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  15. US 10617707

    Oligonucleotides to treat eye disease

    ProQR Therapeutics II B.V. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted
  16. US 10612025

    Antisense oligonucleotides for the treatment of eye disease

    ProQR Therapeutics II B.V. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  17. US 10421963

    Oligonucleotide therapy for leber congenital amaurosis

    ProQR Therapeutics II B.V. · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  18. US 9994856

    Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein

    ProQR Therapeutics II B.V. · Granted Jun 12, 2018 · Expires Jun 7, 2038

    granted
  19. US 9605255

    Oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell

    ProQR Therapeutics II B.V. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted